Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | RARB | P10826 | 9/20 | 0.44 |
| ▸ | RARG | P13631 | 9/20 | 0.44 |
| ▸ | RARA | P10276 | 7/20 | 0.44 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.44 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 7/20 | 0.44 |
| ▸ | RXRB | P28702 | 7/20 | 0.44 |
| ▸ | RXRG | P48443 | 6/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9848328 | 0.79 | ALDH1A1 (0.49) | KDM4EMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL12619017 | 0.77 | ALDH1A1 (0.53) | KDM4EMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL3136514 | 0.74 | ALDH1A1 (0.40) | ALDH1A1BLMTDP1 | |
| SCHEMBL17551922 | 0.71 | KDM4E (0.60) | KDM4EMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL14173250 | 0.71 | ALDH1A1 (0.47) | KDM4EMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL2815307 | 0.71 | ALDH1A1 (0.47) | KDM4EMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL18213884 | 0.71 | KDM4E (0.60) | KDM4EMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL8458491 | 0.70 | ALDH1A1 (0.65) | KDM4EMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL7271322 | 0.70 | KDM4E (0.55) | KDM4EMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL8375020 | 0.70 | RXRA (0.61) | KDM4EMAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288581-B2 | Process for the preparation of functionalised benzocyclobutenes, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2012-10-16 | — | — | US | disclosed |
| US-20120116112-A1 | PROCESS FOR THE PREPARATION OF FUNCTIONALISED BENZOCYCLOBUTENES, AND APPLICATION IN THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | LES LABORATOIRES SERVIER (FR) | 2012-05-10 | — | — | US | disclosed |
| US-8110701-B2 | Process for the preparation of functionalised benzocyclobutenes, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2012-02-07 | — | — | US | disclosed |
| WO-2010007253-A2 | NOVEL METHOD FOR PREPARING FUNCTIONALIZED BENZOCYCLOBUTENES, AND USE IN THE SYNTHESIS OF IVABRADINE AND OF ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | LES LABORATOIRES SERVIER (FR) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016580-A1 | Process for the preparation of functionalised benzocyclobutenes, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2010-01-21 | — | — | US | disclosed |
| EP-2145871-A1 | New method for preparing functionalised benzocyclobutenes and its application to the synthesis of ivabradine and its addition salts with a pharmaceutically acceptable acid. | Les Laboratoires Servier (FR) | 2010-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016580-A1 | Process for the preparation of functionalised benzocyclobutenes, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | BDKRB2, HRH2, C1R | KDM4E 4025/4885MAPT 4869/4885ALDH1A1 652/4885 |
| US-20120116112-A1 | PROCESS FOR THE PREPARATION OF FUNCTIONALISED BENZOCYCLOBUTENES, AND APPLICATION IN THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | CYP4F2, CYP2B6, CYP4F8 | KDM4E 1615/4885MAPT 4825/4885ALDH1A1 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.